GET DAILY SIGNALSAlpha Teknova (TKNO) Posts Record Q3 Revenue with 22% Year-Over-Year Growth
Key Takeaways
- Alpha Teknova reported record third quarter 2026 revenue of $12.7 million, up 22% year over year and above the consensus estimate of $11.64 million.
- The net loss narrowed to $3.5 million, or $0.06 per diluted share, better than the $0.07 loss per share analysts expected and the $0.08 loss reported a year earlier.
- Clinical Solutions revenue jumped 86% to $3.2 million, while Lab Essentials revenue rose 9% to $9.0 million.
- Gross margin expanded to 38.0% from 30.7% in the prior-year quarter, driven by higher revenue and favorable cost absorption.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of roughly $1.0 million.
- Management attributed the momentum to broad-based demand, including a pickup in custom-product orders from small and mid-sized biotech customers.
- For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the additional pages.
- Discover automated trading ideas with Trending AI Robots.
Earnings Context and Why It Matters
Alpha Teknova manufactures critical reagents used in drug discovery, vaccines, and molecular diagnostics. The company continues its multi-year effort to reach profitability. The third quarter of 2026 delivered its second straight record revenue quarter, which suggests that improving biotech funding is starting to lift demand for its custom products. In my view, the results offer a useful test of whether TKNO can maintain double-digit revenue growth, widen margins, and reduce cash burn as the life sciences tools sector stabilizes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Alpha Teknova recorded total revenue of $12.7 million for the third quarter of 2026, a 22% rise from $10.5 million a year earlier and ahead of the $11.64 million consensus estimate. Lab Essentials revenue reached $9.0 million, up 9%, while Clinical Solutions revenue climbed 86% to $3.2 million. Other revenue added $0.5 million.
Gross profit increased to $4.8 million from $3.2 million, lifting the gross margin to 38.0% from 30.7% thanks to higher sales and better fixed-cost absorption. Operating expenses rose to $8.0 million from $7.2 million, largely due to increased sales and marketing outlays. The net loss narrowed to $3.5 million, or $0.06 per diluted share, compared with a $4.3 million loss, or $0.08 per share, in the prior-year quarter and better than the expected $0.07 loss per share. Adjusted EBITDA showed a loss of about $1.0 million. For the first nine months of 2026, revenue totaled $36.0 million versus $30.5 million in the same period of 2025.
Market Reaction and Investor Sentiment
Before the release, sentiment toward TKNO had been turning more constructive as analysts lifted price targets and initiated or upgraded coverage on signs of a biotech funding recovery. The top-line beat and narrower loss reinforced that view, especially the sharp rise in Clinical Solutions revenue and the broad demand management highlighted across life science tools, diagnostics, and biopharma clients. Even so, investors continue to balance ongoing GAAP losses and negative adjusted EBITDA against margin and cash-use progress, so the sustainability of demand remains a key focus for the shares.
Forward Outlook and Key Factors to Monitor
Looking ahead, attention will center on whether TKNO can extend its revenue momentum and keep narrowing losses through the fourth quarter and into 2027. Management has noted that biotech funding improvements usually reach reagent demand with a lag, which could support further order growth in the near term.
The revenue mix between Lab Essentials and the higher-growth Clinical Solutions segment will stay an important margin influence given the company’s high fixed-cost base and its estimate that each additional revenue dollar contributes roughly 70% at the marginal cash level. Commercial investments, including new sales hires, are expected to add more meaningfully by early 2027.
Investors should track gross margin trends, the adjusted EBITDA path, and free cash flow, along with any updates on reaching positive adjusted EBITDA as revenue approaches management targets. External variables such as biotech funding cycles, customer concentration, and input costs will also warrant close attention in coming quarters.
Using Tickeron’s AI Tools for Analysis
When evaluating names in the life sciences tools space, I often turn to Tickeron’s AI Screener to filter opportunities based on technical patterns, fundamentals, and performance metrics. It helps surface comparable companies quickly and supports a more systematic approach to idea generation without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TKNO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 21, 2026
TKNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 32 cases where TKNO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TKNO's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TKNO as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TKNO just turned positive on October 29, 2026. Looking at past instances where TKNO's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Following a +5.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TKNO advanced for three days, in 226 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where TKNO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
TKNO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TKNO crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TKNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TKNO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.321) is normal, around the industry mean (7.659). P/E Ratio (-23.774) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (8.718) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TKNO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TKNO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric